News

Porosome now seeking US patent to cover new treatment for CF

Porosome Therapeutics is seeking a U.S. patent that would cover its “radically new and distinctive” technology platform for the treatment of cystic fibrosis (CF) and other health conditions, the company said in a press release. Its platform works by targeting a cellular structure called the porosome. The global…

Phage therapy shows promise for antibiotic-resistant infections

Bacteriophage therapy could be a promising approach for treating antibiotic-resistant Staphylococcus aureus and Pseudomonas aeruginosa infections in people with cystic fibrosis (CF), according to a small review study. Scientists believe the review, involving three CF patients and two animal models, support moving forward with clinical trials for bacteriophage…

New guidelines outline best tests of exercise ability in CF

An international team of scientists has published new guidelines for how best to perform exercise testing in people with cystic fibrosis (CF). “Guidance and standard operating procedures for functional exercise testing in cystic fibrosis” was published in European Respiratory Review. “Our goal is that all people…

BX004 on fast track to treat P. aeruginosa infections

The U.S. Food and Drug Administration (FDA) has granted fast track designation to BX004, a virus-based therapy that BiomX is developing to treat Pseudomonas aeruginosa bacterial infections in people with cystic fibrosis (CF). The FDA gives this designation to therapies that are designed to address unmet medical…